远端胰腺良性或低级别恶性病变行远端胰腺切除术中自体脾植入与脾切除术的比较:多中心、开放标签、随机对照试验(RESTORE)研究方案
本研究为多中心、随机、开放标签试验方案,拟纳入30例因远端胰腺良性或低级别恶性病变需行微创远端胰腺切除联合脾切除术的患者,随机分配至术中额外行自体脾植入(干预组)或不进一步干预(对照组),另设15例保留脾脏的远端胰腺切除术患者作为脾功能正常的对照组。术后6个月接种伤寒沙门菌多糖疫苗,以接种前后特异性抗体滴度比值作为主要结局指标,评估自体脾植入后的脾免疫功能。
要点
- 拟纳入30例微创远端胰腺切除联合脾切除患者,随机分为自体脾植入组与对照组,另设15例保脾手术患者为正常脾功能对照。
- 术后6个月接种伤寒沙门菌(Typhim Vi™)多糖疫苗,以接种前后特异性抗体滴度比值作为主要结局指标。
- 次要结局包括术中细节、住院时长、30天死亡率和发病率。
核心结论
- 本研究将评估微创远端胰腺切除联合脾切除术中行自体脾植入后的脾免疫功能,结果将揭示自体脾植入后脾功能的相关细节,并指导脾切除不可避免时患者的进一步治疗选择。
研究设计与样本
- 多中心、随机、开放标签试验方案。
- 30例因远端胰腺良性或低级别恶性病变需行微创远端胰腺切除联合脾切除术的参与者,随机分配至术中额外行自体脾植入(干预组)或不进一步干预(对照组)。
- 另设15例将行保留脾脏的远端胰腺切除术的患者作为脾功能正常的对照组。
主要发现
- 术后6个月,在假定脾功能恢复后,给予伤寒沙门菌(Typhim Vi™)疫苗,该疫苗为多糖疫苗。
- 测量接种前即刻及接种后4至6周的特异性抗体滴度。
- 接种前后抗体计数比值是主要结局指标。
- 次要结局指标包括术中细节、住院时长、30天死亡率和发病率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The spleen plays a significant role in the clearance of circulating microorganisms. Sequelae of splenectomy, especially immunodeficiency, can have a deleterious effect on a patient's health and even lead to death. Hence, splenectomy should be avoided and spleen preservation during elective surgery has become a treatment goal. However, this cannot be achieved in every patient due to intraoperative technical difficulties or oncological reasons. Autogenic splenic implantation (ASI) is currently the only possible way to preserve splenic function when a splenectomy is necessary. Experience largely stems from trauma patients with a splenic rupture. Splenic immune function can be measured by the body's clearing capacity of encapsulated bacteria. The aim of this study is to assess the splenic immune function after ASI was performed during minimally invasive (laparoscopic or robotic) distal pancreatectomy with splenectomy. METHODS: This is the protocol for a multicentre, randomized, open-labelled trial. Thirty participants with benign or low-grade malignant lesions of the distal pancreas requiring minimally invasive distal pancreatectomy and splenectomy will be allocated to either additional intraoperative ASI (intervention) or no further intervention (control). An additional 15 patients who will undergo spleen-preserving distal pancreatectomy serve as the control group with normal splenic function. Six months postoperatively, after assumed restoration of splenic function, patients will be given a Salmonella typhi (Typhim Vi™) vaccine. The Salmonella typhi vaccine is a polysaccharide vaccine. The specific antibody titres immediately before and 4 to 6 weeks after vaccination will be measured. The ratio between pre- and post-vaccination antibody count is the primary outcome measure and secondary outcome measures include intraoperative details, length of hospital stay, 30-day mortality and morbidity. DISCUSSION: This study will investigate the splenic immune function of patients who undergo ASI during minimally invasive distal pancreatectomy with splenectomy. The splenic immune function will be measured using the surrogate outcome of specific antibody titre after vaccination with a Salmonella typhi vaccine. The results will reveal details about splenic function after ASI and guide further treatment options for patients when a splenectomy cannot be avoided. It might eventually lead to a new standard of care making sometimes more demanding and time-consuming spleen-preserving procedures redundant. TRIAL REGISTRATION: International Standard Randomized Controlled Trials Number (ISRCTN) ISRCTN10171587. Prospectively registered on 18 February 2019.
引用
- Hilal MA, Kuemmerli C, Sijberden JP, et al. Autogenic splenic implantation versus splenectomy in patients undergoing distal pancreatectomy for benign or low-grade malignant lesions of the distal pancreas: study protocol for a multicentre, open-label, randomized controlled trial (RESTORE). Trials. 2024. PMID: 38195501. doi:10.1186/s13063-023-07714-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。